权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Imaging and Dosimetry of Yttrium-90 for Personalized Cancer Treatment

用于个性化癌症治疗的 Yttrium-90 成像和剂量测定

基本信息

批准号：
10669186
负责人：
YUNI K DEWARAJA
金额：
$ 68.43万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-15 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10669186
关键词：
90Y Acceleration Address Adoption Cancer Etiology Cessation of life Clinic Clinical Clinical Research Clinical Trials Complex Data Disease Dose Evaluable Disease External Beam Radiation Therapy Failure Foundations Funding Future Goals Hepatotoxicity Image Joint repair Joints Lesion Liver Liver parenchyma Malignant Neoplasms Maps Mathematics Methods Microspheres Modality Modeling Motivation Noise PET/CT scan Patient-Focused Outcomes Patients Performance Phase Phase I Clinical Trials Photons Physics Pilot Projects Positron-Emission Tomography Primary carcinoma of the liver cells Process Public Health Radiation Radiation Dose Unit Radiation Tolerance Radiation therapy Radioembolization Radionuclide therapy Reporting Safety Scanning Testing Toxic effect Training absorption clinical practice clinically relevant convolutional neural network deep learning denoising dosimetry image reconstruction imaging Segmentation improved innovation internal radiation learning strategy multimodal data multimodality next generation novel novel strategies personalized cancer therapy phase II trial prospective radiation delivery reconstruction response single photon emission computed tomography standard of care tool trial design tumor

项目摘要

Abstract Selective internal radiation therapy (SIRT) with preferential delivery of 90Y microspheres to target lesions has shown promising response rates with limited toxicity in the treatment of hepatocellular (HCC), the second leading cause of cancer death in the world. However, to achieve more durable responses, there is much room to improve/adapt the treatment to ensure that all lesions and lesion sub-regions receive adequate radiation delivery. While externally delivered stereotactic body radiation therapy (SBRT) is well suited for smaller solitary HCC, its application for larger or multifocal disease is challenged by the radiation tolerance of the normal liver parenchyma. A dosimetry guided combined approach that exploits complementary advantages of internal and external radiation delivery can be expected to improve treatment of HCC. To make this transition, however, prospective clinical trials establishing safety are needed. Furthermore, for routine clinic use, accurate and fast voxel-level dose estimation in internal radionuclide therapy, that lags behind external beam therapy dosimetry, is still needed. Our long-term goal is to improve the efficacy of radiation therapy with personalized dosimetry guided treatment. Our objective in this application is to demonstrate that it is possible to use 90Y imaging based absorbed dose estimates after SIRT to safely deliver external radiation to target regions (voxels) that are predicted to be underdosed and to develop deep learning based tools to make voxel-level internal dose estimation practical for routine clinic use. Specifically, in Aim 1, we will perform a Phase 1 clinical trial in HCC patients where we will take the novel approach of using the 90Y PET/CT derived absorbed dose map after SIRT to deliver SBRT to tumor regions predicted to be underdosed based on previously established dose-response models. The primary objective of the trial is to obtain estimates of safety of combined SIRT+SBRT for future Phase II trial design. In parallel, in Aim 2, building on promising initial results we will develop novel deep learning based tools for 90Y PET/CT and SPECT/CT reconstruction, joint reconstruction-segmentation and scatter estimation under the low count-rate setting, typical for 90Y. These methods have a physics/mathematics foundation, where convolutional neural networks (CNNs) are included within the iterative reconstruction process, instead of post-reconstruction denoising. In Aim 3, we will develop a CNN for fast voxel-level dosimetry and combine with the CNNs of Aim 2 to develop an innovative end-to-end framework with unified dosimetry-task based training. At the end of this study, we will be ready to use the new deep learning tools in a Phase II trial to demonstrate enhanced efficacy with SIRT+SBRT compared with SIRT alone and advance towards our long- term goal. This will accelerate adoption of these next-generation tools in clinical practice and will have a significant positive impact because treatment based on patient specific dosimetry will substantially improve efficacy, compared with current standard practice in SIRT. Although we focus on 90Y SIRT, our tools will be applicable in radionuclide therapy in general, a rapidly advancing treatment option.

抽象的优先将 90Y 微球递送至目标病灶的选择性体内放射治疗 (SIRT) 在肝细胞 (HCC) 治疗中显示出有希望的反应率和有限的毒性，这是第二大主要疾病世界上癌症死亡的原因。然而，为了实现更持久的应对措施，还有很大的空间改进/调整治疗，以确保所有病变和病变子区域接受足够的放射治疗。虽然体外立体定向放射治疗 (SBRT) 非常适合较小的孤立性 HCC，但其正常肝脏的辐射耐受性对较大或多灶性疾病的应用提出了挑战薄壁组织。剂量测定引导的组合方法，利用内部和外部的互补优势外部放射治疗有望改善 HCC 的治疗。然而，为了实现这一转变，需要进行前瞻性临床试验来确定安全性。此外，对于常规临床使用，准确、快速内部放射性核素治疗中的体素水平剂量估计落后于外部束治疗剂量测定，仍然需要。我们的长期目标是通过个性化剂量测定提高放射治疗的疗效指导治疗。我们在此应用中的目标是证明可以使用基于 90Y 成像的 SIRT 后的吸收剂量估计，以安全地将外部辐射传递到目标区域（体素） predicted to be underdosed and to develop deep learning based tools to make voxel-level internal dose 估计对于常规临床使用实用。具体来说，在目标 1 中，我们将针对 HCC 进行一期临床试验我们将在 SIRT 后采取使用 90Y PET/CT 得出的吸收剂量图的新方法的患者根据先前建立的剂量反应，将 SBRT 递送至预计剂量不足的肿瘤区域模型。该试验的主要目的是获得对未来 SIRT+SBRT 组合安全性的估计 II 期试验设计。与此同时，在目标 2 中，我们将在有希望的初步成果的基础上开发新颖的深度学习基于 90Y PET/CT 和 SPECT/CT 重建、联合重建-分割和散射的工具低计数率设置下的估计，典型值为 90Y。这些方法具有物理/数学基础，其中卷积神经网络（CNN）包含在迭代重建过程中，而不是重建后去噪。在目标 3 中，我们将开发一个用于快速体素级剂量测定的 CNN 与 Aim 2 的 CNN 相结合，开发具有统一剂量测定任务的创新端到端框架基础培训。在本研究结束时，我们将准备在第二阶段试验中使用新的深度学习工具与单独 SIRT 相比，证明 SIRT+SBRT 的疗效增强，并朝着我们的长期目标迈进学期目标。这将加速这些下一代工具在临床实践中的采用，并将产生显着的积极影响，因为基于患者特定剂量测定的治疗将大大改善与当前 SIRT 标准实践相比的疗效。虽然我们专注于 90Y SIRT，但我们的工具将一般适用于放射性核素治疗，这是一种快速发展的治疗选择。